NCM
SLNO

Nantahala Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Nantahala Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-600,000
Closed -$42.9M – 168
2025
Q1 		$42.9M Buy
+600,000
New +$29.2M 1.7% 11

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nantahala Capital Management's SLNO Position: Q1 2026 in Review

Nantahala Capital Management increased its Soleno Therapeutics (SLNO) stake by 33% in Q1 2026, buying an estimated $16.9M and bringing the position to 1,744,124 shares worth $58.4M. The position accounts for 2.15% of the portfolio, ranked #8.

Nantahala Capital Management first reported a position in SLNO in Q4 2019 and has held it in 26 quarters since. The position peaked at $177M in Q4 2024. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Nantahala Capital Management held 1,744,124 shares of Soleno Therapeutics worth $58.4M as of Q1 2026.
  • Nantahala Capital Management bought 430,122 Soleno Therapeutics shares in Q1 2026, an estimated $16.9M.
  • Soleno Therapeutics made up 2.15% of Nantahala Capital Management's portfolio in Q1 2026, its #8 holding.
  • Nantahala Capital Management first reported a position in Soleno Therapeutics in Q4 2019 and has held it in 26 quarters since.
  • Nantahala Capital Management's Soleno Therapeutics position peaked at $177M in Q4 2024.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.